DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Home » Topics A–Z » Granuloma faciale
Author: Vanessa Ngan, Staff Writer, 2003.
Granuloma faciale is a rare, non-cancerous skin disorder that is characterised by single or multiple papules, plaques or nodules, most often occurring on the face.
Granuloma faciale most often affects healthy middle-aged white men, although it has been found in males and females of all races and ages.
Patients most often present to their doctor after noticing a spot or lesion on their face that then enlarges or multiplies in number over several weeks or months. These lesions are usually:
Granuloma faciale is usually symptomless. Some patients may complain of tender, itching or stinging lesions.
Why granuloma faciale occurs remains unknown but sun exposure has been implicated:
Diagnosis is confirmed by skin biopsy and is often necessary to rule out other skin diseases that have similar appearance. Granuloma faciale is characterised by inflammatory cells in the dermis including eosinophils (allergy cells) and vasculitis (inflamed blood vessels).
Skin conditions that may appear similar to granuloma faciale include:
Granuloma faciale is a chronic condition with exacerbations and remissions. Spontaneous resolution rarely occurs. The disease appears not to have any relationship to internal disease and treatment is mainly to improve the appearance. Various medical and surgical therapies have been used but none have been consistently successful. Granuloma faciale also has the tendency to recur after treatment.
Medical therapies used with varying results include:
Surgical therapy may also be used. Results are variable and may leave scarring.
See smartphone apps to check your skin.
[Sponsored content]
See the DermNet NZ bookstore
© 2021 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.